Analysis of severe adverse effects following community-based ivermectin treatment in the Democratic Republic of Congo

[1]  Y. Coppieters,et al.  Untreated villages and factors associated with the absence of Community-Directed Treatment with Ivermectin (CDTI) in DRC. , 2018, Journal of infection in developing countries.

[2]  D. Fletcher,et al.  “Test and not treat” for onchocerciasis control in a Loa loa endemic area , 2017, The New England Journal of Medicine.

[3]  R. Eversole,et al.  Ivermectin treatment of Loa loa hyper-microfilaraemic baboons (Papio anubis): Assessment of microfilarial load reduction, haematological and biochemical parameters and histopathological changes following treatment , 2017, PLoS neglected tropical diseases.

[4]  D. Bakajika,et al.  Central and Peripheral Nervous System Disorders Following Ivermectin Mass Administration: A Descriptive Study Based on the Democratic Republic of Congo Pharmacovigilance System , 2017, Drugs - Real World Outcomes.

[5]  D. Engels.  UNPRECEDENTED PROGRESS AGAINST NEGLECTED TROPICAL DISEASES, WHO REPORTS , 2017, Saudi Medical Journal.

[6]  B. Currie,et al.  Pediatric melioidosis in Sarawak, Malaysia: Epidemiological, clinical and microbiological characteristics , 2017, PLoS neglected tropical diseases.

[7]  M. Murdoch,et al.  Pre-control relationship of onchocercal skin disease with onchocercal infection in Guinea Savanna, Northern Nigeria , 2017, PLoS neglected tropical diseases.

[8]  M. Murdoch,et al.  Onchocerciasis in the Democratic Republic of Congo: Survey of knowledge, attitude and perception in Bandundu province. , 2017, Journal of infection and public health.

[9]  R. Cheke.  Factors affecting onchocerciasis transmission: lessons for infection control , 2017, Expert review of anti-infective therapy.

[10]  J. Beier,et al.  Onchocerciasis in Yemen: Time to take action against a neglected tropical parasitic disease. , 2016, Acta tropica.

[11]  A. Zeynudin,et al.  Impact of Six Years Community Directed Treatment with Ivermectin in the Control of Onchocerciasis, Western Ethiopia , 2016, PloS one.

[12]  M. Murdoch,et al.  Onchocerciasis control in the Democratic Republic of Congo (DRC): challenges in a post‐war environment , 2015, Tropical medicine & international health : TM & IH.

[13]  J. Oteo,et al.  Neotrombicula inopinata (Acari: Trombiculidae) – a possible causative agent of trombiculiasis in Europe , 2014, Parasites & Vectors.

[14]  Fitsum Weldegebreal,et al.  Assessment of community’s knowledge, attitude and practice about onchocerciasis and community directed treatment with Ivermectin in Quara District, north western Ethiopia , 2014, Parasites & Vectors.

[15]  T. Geary,et al.  The lack of influence of food and local alcoholic brew on the blood level of Mectizan(®) (ivermectin). , 2013, Acta tropica.

[16]  K. Müller-Vahl,et al.  The therapeutic potential of cannabis and cannabinoids. , 2012, Deutsches Arzteblatt international.

[17]  S. Wanji,et al.  Changes in stigma and discrimination of onchocerciasis in Africa. , 2012, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[18]  V. Oguoma,et al.  Onchocerciasis in Anambra State, Southeast Nigeria: clinical and psychological aspects and sustainability of community directed treatment with ivermectin (CDTI) , 2010, Postgraduate Medical Journal.

[19]  B. Boatin.  The Onchocerciasis Control Programme in West Africa (OCP) , 2008, Annals of tropical medicine and parasitology.

[20]  M. Sauerbrey.  The Onchocerciasis Elimination Program for the Americas (OEPA) , 2008, Annals of tropical medicine and parasitology.

[21]  M. Boussinesq,et al.  Encephalopathy after ivermectin treatment in a patient infected with Loa loa and Plasmodium spp. , 2008, The American journal of tropical medicine and hygiene.

[22]  E. Braide,et al.  Adverse reactions from community directed treatment with ivermectin (CDTI) for onchocerciasis and loiasis in Ondo State, Nigeria. , 2007, Revista de biologia tropical.

[23]  M. Boussinesq,et al.  Randomized, controlled, double-blind trial with ivermectin on Loa loa microfilaraemia: efficacy of a low dose (∼25 μg/kg) versus current standard dose (150 μg/kg) , 2007 .

[24]  M. Boussinesq,et al.  African Programme for Onchocerciasis Control (APOC): sociological study in three foci of central Africa before the implementation of treatments with ivermectin (Mectizan). , 2007, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[25]  M. Boussinesq,et al.  Randomized, controlled, double-blind trial with ivermectin on Loa loa microfilaraemia: efficacy of a low dose (approximately 25 microg/kg) versus current standard dose (150 microg/kg). , 2007, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[26]  J. Bonnetblanc,et al.  Effets secondaires de l’ivermectine utilisée dans le traitement de la gale , 2006 .

[27]  María-Gloria Basáñez,et al.  River Blindness: A Success Story under Threat? , 2006, PLoS medicine.

[28]  Y. Ilan,et al.  Histamine dihydrochloride: actions and efficacy in the treatment of chronic hepatitis C infection , 2006, Expert review of anti-infective therapy.

[29]  D. Kayembe,et al.  [African Program for Onchocerciasis Control (APOC): Onchocerca volvulus transmission by Simulium damnosum s. l. in two regions of the Central African Republic]. , 2006, Parasite.

[30]  J. Bonnetblanc,et al.  [Systemic adverse reactions with ivermectin treatment of scabies]. , 2006, Annales de dermatologie et de venereologie.

[31]  W. Oyibo,et al.  Adverse reactions following annual ivermectin treatment of onchocerciasis in Nigeria. , 2003, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[32]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[33]  M. Murdoch,et al.  Onchocerciasis: the clinical and epidemiological burden of skin disease in Africa , 2002, Annals of tropical medicine and parasitology.

[34]  M. Boussinesq,et al.  Ocular findings after ivermectin treatment of patients with high Loa loa microfilaremia , 2000, Ophthalmic epidemiology.

[35]  S. Ranque,et al.  Impact of repeated large scale ivermectin treatments on the transmission of Loa loa. , 1998, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[36]  B. Benton.  Economic impact of onchocerciasis control through the African Programme for Onchocerciasis Control: an overview. , 1998, Annals of tropical medicine and parasitology.

[37]  L. Fourcade,et al.  Efficacy of ivermectin treatment of Loa loa filariasis patients without microfilaraemias. , 1994, Annals of Tropical Medicine and Parasitology.

[38]  T. Cox,et al.  Regression of hepatic lesions after treatment of Schistosoma mansoni or Schistosoma japonicum infection in mice: a comparative study. , 1993, The American journal of tropical medicine and hygiene.

[39]  J. Chodakewitz,et al.  Tolerance and efficacy of single high-dose ivermectin for the treatment of loiasis. , 1993, The American journal of tropical medicine and hygiene.

[40]  S. Ranque,et al.  Adverse reactions following ivermectin treatment in hyperendemic loiasis area , 1993 .

[41]  F. Chandre,et al.  Ivermectin treatment of loiasis. , 1992, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[42]  A. Datry,et al.  [Value of ivermectin in the initial treatment of loaiasis]. , 1991, Presse medicale.

[43]  E. Rupp,et al.  Ivermectin in loiasis and concomitant O. volvulus and M. perstans infections. , 1988, The American journal of tropical medicine and hygiene.